News & Updates

COVID-19 vaccine safe to administer in first trimester of pregnancy, study says

21 Aug 2024

Among pregnant women, exposure to mRNA COVID-19 vaccine in the first trimester does not appear to contribute to an increased risk of selected major structural birth defects, according to a retrospective study.

COVID-19 vaccine safe to administer in first trimester of pregnancy, study says

21 Aug 2024

Shingles vax tied to reduced dementia risk

20 Aug 2024 by

Immunization with the non-live recombinant zoster vaccine (RZV) or live-attenuated zoster vaccine (ZVL) is associated with reductions in the risk of dementia relative to the 23-valent pneumococcal polysaccharide vaccine (PPSV23), according to a large observational study in adults aged ≥50 years.

Shingles vax tied to reduced dementia risk

20 Aug 2024

Is long-acting cabotegravir safe as PrEP for expecting mothers?

20 Aug 2024 by

The use of long-acting injectable cabotegravir (CAB-LA) as a pre-exposure prophylaxis (PrEP) during pregnancy appears to be safe and well tolerated in cisgender women, according to the initial data of HPTN* 084 open-label extension (OLE) study presented at AIDS 2024.

Is long-acting cabotegravir safe as PrEP for expecting mothers?

20 Aug 2024

Dual-indication bivalent RSV vaccine now available in HK: Maternal immunization data

20 Aug 2024

Respiratory syncytial virus (RSV) prefusion F protein–based (RSVpreF) vaccine, a single-dose bivalent vaccine against RSV A and RSV B, is now available in Hong Kong for prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to 6 months of age through active immunization of pregnant individuals at a gestational age of 32–36 weeks, and for prevention of LRTD caused by RSV in individuals aged ≥60 years.

Dual-indication bivalent RSV vaccine now available in HK: Maternal immunization data

20 Aug 2024

Bivalent dual-indication RSVpreF vaccine: Data in older individuals

19 Aug 2024

A bivalent respiratory syncytial virus (RSV) prefusion F protein–based (RSVpreF) vaccine is now available in Hong Kong for prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals ≥60 years of age, and for prevention of LRTD and severe LRTD caused by RSV in infants from birth up to 6 months of age through active immunization of pregnant individuals at a gestational age of 32–36 weeks.

Bivalent dual-indication RSVpreF vaccine: Data in older individuals

19 Aug 2024

Multistrain probiotics do not reduce multidrug-resistant organisms in preemies

14 Aug 2024

In preterm infants, the use of multistrain probiotics does not appear to prevent colonization with multidrug-resistant organisms or highly epidemic bacteria (MDRO+), as shown in the phase III PRIMAL* trial.

Multistrain probiotics do not reduce multidrug-resistant organisms in preemies

14 Aug 2024

Education package improves pharmacist knowledge, confidence on HIV management

14 Aug 2024

A pharmacy-specific, foundational HIV management education package can help improve pharmacist knowledge in HIV management and self-reported confidence in managing this specialty area, suggests a recent study.

Education package improves pharmacist knowledge, confidence on HIV management

14 Aug 2024

The next Berlin patient: 7th to join pool of HIV patients achieving sustained remission

13 Aug 2024 by

A new patient achieves sustained HIV remission – the seventh in the world – following stem cell therapy for blood cancer and after stopping antiretroviral therapy (ART), adding to the roster of individuals with HIV who are inching their way towards a potential cure.

The next Berlin patient: 7th to join pool of HIV patients achieving sustained remission

13 Aug 2024

Managing COVID-19 in vulnerable adults

12 Aug 2024 by

Despite the success of COVID-19 vaccines, immunocompromised individuals, older adults and those with comorbidities remain at disproportionately high risk of severe outcomes from COVID-19. This underscores the need for additional preventive measures for these vulnerable populations. At the Advances in Medicine (AIM) 2024 conference, Professor Barnaby Young from the National Centre for Infectious Diseases, Singapore, shared insights on current COVID-19 management practices, including the important role of antivirals, such as remdesivir (Veklury^®, Gilead), in treatment of vulnerable patients.

Managing COVID-19 in vulnerable adults

12 Aug 2024

Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women

12 Aug 2024 by

In the interim analysis of the pivotal phase III PURPOSE 1 trial, twice-yearly subcutaneous lenacapavir, a first-in-class, high-potency HIV-1 capsid inhibitor, shows 100-percent efficacy and superiority to background HIV (bHIV*) incidence and daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF**) for pre-exposure prophylaxis (PrEP) in HIV-negative cisgender women.

Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women

12 Aug 2024

News & Updates

Filter by Specialty:

Specialty:

COVID-19 vaccine safe to administer in first trimester of pregnancy, study says

COVID-19 vaccine safe to administer in first trimester of pregnancy, study says

Shingles vax tied to reduced dementia risk

Shingles vax tied to reduced dementia risk

Is long-acting cabotegravir safe as PrEP for expecting mothers?

Is long-acting cabotegravir safe as PrEP for expecting mothers?

Dual-indication bivalent RSV vaccine now available in HK: Maternal immunization data

Dual-indication bivalent RSV vaccine now available in HK: Maternal immunization data

Bivalent dual-indication RSVpreF vaccine: Data in older individuals

Bivalent dual-indication RSVpreF vaccine: Data in older individuals

Multistrain probiotics do not reduce multidrug-resistant organisms in preemies

Multistrain probiotics do not reduce multidrug-resistant organisms in preemies

Education package improves pharmacist knowledge, confidence on HIV management

Education package improves pharmacist knowledge, confidence on HIV management

The next Berlin patient: 7th to join pool of HIV patients achieving sustained remission

The next Berlin patient: 7th to join pool of HIV patients achieving sustained remission

Managing COVID-19 in vulnerable adults

Managing COVID-19 in vulnerable adults

Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women

Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women